Patient characteristics
| No . | Sex . | Age . | Rai stage . | CD38 . | IgVH . | Previous therapies . | Genetic aberrations . |
|---|---|---|---|---|---|---|---|
| 1 | Male | 79 | I | neg | UM | A | del 17p13, complex karyotype |
| 2 | Male | 67 | III | neg | UM | A | del 17p13, complex karyotype |
| 3 | Female | 71 | IV | neg | UM | RB | del 17p13, complex karyotype |
| 4 | Female | 60 | IV | pos | M | Clb, ClbP | del 17p13, t trisomy12, del14q24.1-q32.33 |
| 5 | Male | 68 | II | pos | M | Clb, FC | del 17p13, trisomy 12 |
| 6 | Male | 62 | II | pos | UM | Clb, ClbP | del 17p13, complex karyotype |
| 7 | Male | 54 | II | neg | UM | RB, FCR | del 11q22, del 13q14 |
| 8 | Male | 78 | II | pos | UM | RB | del 13q14, del 11q14.3-23.3, gain 15q22.31-26.3 |
| 9 | Male | 72 | II | neg | UM | R-Clb, RB | 11q11.1-q23.3, del 13q14 |
| 10 | Male | 71 | III | neg | M | ClbP, R | del 11q22.3-q23.3, del 15q26.1-q26.2 |
| 11 | Female | 68 | 0 | ND | M | ClbP, RB | del 11q14.1-q23.3, complex karyotype |
| 12 | Male | 62 | IV | neg | UM | F, FCR | |
| 13 | Male | 67 | II | neg | UM | FCR, R-CHOP | del 11q22, trisomy 12, complex karyotype |
| 14 | Male | 49 | II | neg | UM | FC, RB | del 11q14.1-q23.3, complex karyotype |
| 15 | Male | 74 | 0 | ND | M | none | del 5q31.3, del 13q14, del 13q31.1, del 22q11.21 |
| 16 | Male | 49 | II | pos | UM | FCR | trisomy 12, trisomy 19 |
| 17 | Male | 62 | II | neg | M | Clb | trisomy 12, del 13q14, biclonal |
| 18 | Female | 77 | I | neg | M | F, B | Trisomy 12, trisomy 22 |
| 19 | Female | 79 | IV | pos | M | Clb | trisomy 12, del 13q14, biclonal |
| 20 | Male | 70 | I | pos | UM | FCR | trisomy 12 |
| 21 | Male | 71 | III | pos | UM | ClbP | del 13q14 |
| 22 | Male | 55 | II | neg | M | none | trisomy 12, del 13q14 |
| 23 | Female | 66 | II | pos | M | Clb | trisomy 12, del 13q14 |
| 24 | Male | 72 | IV | neg | M | ClbP | del 13q14 |
| 25 | Male | 79 | IV | neg | M | ClbP, COP | del 13q14 |
| 26 | Female | 84 | 0 | neg | M | Clb | del 13q14 |
| 27 | Male | 60 | II | pos | UM | ClbP | del 13q14 |
| 28 | Male | 46 | IV | neg | M | none | del 13q |
| 29 | Male | 67 | II | neg | M | none | del 13q14 |
| 30 | Male | 75 | 0 | neg | M | Clb | del 13q14 bi-allelic |
| 31 | Male | 69 | II | neg | M | none | del 13q14 |
| 32 | Male | 77 | 0 | neg | M | none | del 13q14 bi-allelic |
| 33 | Male | 74 | 0 | neg | UM | Clb | del 17p13, complex karyotype |
| 34 | Male | 59 | II | neg | UM | A | del 17p13, del 13q14 |
| 35 | Female | 72 | 0 | pos | M | ClbP | del 17p13 |
| 36 | Male | 61 | III | neg | M | ClbP | del 17p13, complex karyotype |
| 37 | Male | 78 | II | pos | M | none | trisomy 12 |
| 38 | Male | 72 | II | neg | UM | Clb, ClbP | trisomy 12 |
| 39 | Female | 47 | II | neg | M | none | del 13q14 |
| 40 | Male | 74 | 0 | neg | M | none | del 13q14 |
| No . | Sex . | Age . | Rai stage . | CD38 . | IgVH . | Previous therapies . | Genetic aberrations . |
|---|---|---|---|---|---|---|---|
| 1 | Male | 79 | I | neg | UM | A | del 17p13, complex karyotype |
| 2 | Male | 67 | III | neg | UM | A | del 17p13, complex karyotype |
| 3 | Female | 71 | IV | neg | UM | RB | del 17p13, complex karyotype |
| 4 | Female | 60 | IV | pos | M | Clb, ClbP | del 17p13, t trisomy12, del14q24.1-q32.33 |
| 5 | Male | 68 | II | pos | M | Clb, FC | del 17p13, trisomy 12 |
| 6 | Male | 62 | II | pos | UM | Clb, ClbP | del 17p13, complex karyotype |
| 7 | Male | 54 | II | neg | UM | RB, FCR | del 11q22, del 13q14 |
| 8 | Male | 78 | II | pos | UM | RB | del 13q14, del 11q14.3-23.3, gain 15q22.31-26.3 |
| 9 | Male | 72 | II | neg | UM | R-Clb, RB | 11q11.1-q23.3, del 13q14 |
| 10 | Male | 71 | III | neg | M | ClbP, R | del 11q22.3-q23.3, del 15q26.1-q26.2 |
| 11 | Female | 68 | 0 | ND | M | ClbP, RB | del 11q14.1-q23.3, complex karyotype |
| 12 | Male | 62 | IV | neg | UM | F, FCR | |
| 13 | Male | 67 | II | neg | UM | FCR, R-CHOP | del 11q22, trisomy 12, complex karyotype |
| 14 | Male | 49 | II | neg | UM | FC, RB | del 11q14.1-q23.3, complex karyotype |
| 15 | Male | 74 | 0 | ND | M | none | del 5q31.3, del 13q14, del 13q31.1, del 22q11.21 |
| 16 | Male | 49 | II | pos | UM | FCR | trisomy 12, trisomy 19 |
| 17 | Male | 62 | II | neg | M | Clb | trisomy 12, del 13q14, biclonal |
| 18 | Female | 77 | I | neg | M | F, B | Trisomy 12, trisomy 22 |
| 19 | Female | 79 | IV | pos | M | Clb | trisomy 12, del 13q14, biclonal |
| 20 | Male | 70 | I | pos | UM | FCR | trisomy 12 |
| 21 | Male | 71 | III | pos | UM | ClbP | del 13q14 |
| 22 | Male | 55 | II | neg | M | none | trisomy 12, del 13q14 |
| 23 | Female | 66 | II | pos | M | Clb | trisomy 12, del 13q14 |
| 24 | Male | 72 | IV | neg | M | ClbP | del 13q14 |
| 25 | Male | 79 | IV | neg | M | ClbP, COP | del 13q14 |
| 26 | Female | 84 | 0 | neg | M | Clb | del 13q14 |
| 27 | Male | 60 | II | pos | UM | ClbP | del 13q14 |
| 28 | Male | 46 | IV | neg | M | none | del 13q |
| 29 | Male | 67 | II | neg | M | none | del 13q14 |
| 30 | Male | 75 | 0 | neg | M | Clb | del 13q14 bi-allelic |
| 31 | Male | 69 | II | neg | M | none | del 13q14 |
| 32 | Male | 77 | 0 | neg | M | none | del 13q14 bi-allelic |
| 33 | Male | 74 | 0 | neg | UM | Clb | del 17p13, complex karyotype |
| 34 | Male | 59 | II | neg | UM | A | del 17p13, del 13q14 |
| 35 | Female | 72 | 0 | pos | M | ClbP | del 17p13 |
| 36 | Male | 61 | III | neg | M | ClbP | del 17p13, complex karyotype |
| 37 | Male | 78 | II | pos | M | none | trisomy 12 |
| 38 | Male | 72 | II | neg | UM | Clb, ClbP | trisomy 12 |
| 39 | Female | 47 | II | neg | M | none | del 13q14 |
| 40 | Male | 74 | 0 | neg | M | none | del 13q14 |
Complex karyotype: more than 4 aberrations.
A, alemtuzumab; B, bendamustin; Clb, chlorambucil; ClbP, chlorambucil 1 prednisone; COP, cyclophosphamide1 vincristine 1 prednisolone; F, fludarabine; FC, fludarabine 1 cyclophosphamide; FCR, fludarabine1cyclophosphamide1rituximab; M, mutated; ND, not done; R, rituximab; RB, rituximab 1 bendamustin; R-CHOP, rituximab 1 cyclophosphamide 1 doxorubicin1 vincristine 1 prednisolone; R-Clb, rituximab1chlorambucil; UM, unmutated.